Atea Pharmaceuticals Inc
AVIR3.270USD
+0.020+0.62%
收盤 11/07, 16:00（美東）報價延遲15分鐘
265.32M總市值
虧損本益比TTM
關於 Atea Pharmaceuticals Inc 公司
Atea Pharmaceuticals, Inc. 是一家臨牀階段的生物製藥公司。該公司專注於發現、開發和商業化抗病毒療法，以改善患有嚴重病毒感染的患者的生活。該公司正在進行一項 3 期臨牀試驗，評估 bemnifosbuvir 治療 2019 冠狀病毒病 (COVID-19) 的效果。該公司還正在進行一項 2 期臨牀試驗，評估 bemnifosbuvir 和 ruzasvir 聯合治療丙型肝炎病毒 (HCV) 的效果。bemnifosbuvir (AT-527) 是一種研究性、新型、口服鳥苷核苷酸類似物聚合酶抑制劑，它將獨特的核苷酸支架與新型雙前體藥物相結合，旨在抑制病毒複製的核心酶。SUNRISE-3 旨在評估 bemnifosbuvir 作爲單一療法的效果，但它也在探索聯合療法對較小部分患者的影響。
Atea Pharmaceuticals Inc簡介
公司代碼AVIR
公司名稱Atea Pharmaceuticals Inc
上市日期Oct 30, 2020
CEODr. Jean-Pierre Sommadossi, Ph.D.
員工數量56
證券類型Ordinary Share
年結日Oct 30
公司地址225 Franklin Street
城市BOSTON
上市交易所NASDAQ Global Select Consolidated
國家United States of America
郵編02110
電話18572048109
網址https://ateapharma.com/
公司代碼AVIR
上市日期Oct 30, 2020
CEODr. Jean-Pierre Sommadossi, Ph.D.
Atea Pharmaceuticals Inc公司高管
名稱
名稱/職務
職務
持股
持股變動
Ms. Andrea J. Corcoran, J.D.
Ms. Andrea J. Corcoran, J.D.
Chief Financial Officer, Executive Vice President, Legal, and Secretary
Chief Financial Officer, Executive Vice President, Legal, and Secretary
717.31K
+1.18%
Dr. Jean-Pierre Sommadossi, Ph.D.
Dr. Jean-Pierre Sommadossi, Ph.D.
Chairman of the Board, President, Chief Executive Officer, Founder
Chairman of the Board, President, Chief Executive Officer, Founder
300.94K
--
Mr. John Vavricka
Mr. John Vavricka
Chief Commercial Officer
Chief Commercial Officer
134.59K
--
Mr. Bruno Lucidi
Mr. Bruno Lucidi
Independent Director
Independent Director
112.75K
+35.60%
Dr. Bruce Polsky, M.D.
Dr. Bruce Polsky, M.D.
Independent Director
Independent Director
95.21K
+45.12%
Dr. Polly A. Murphy, DVM, Ph.D.
Dr. Polly A. Murphy, DVM, Ph.D.
Independent Director
Independent Director
86.05K
+52.44%
Dr. Maria Arantxa Horga, M.D.
Dr. Maria Arantxa Horga, M.D.
Chief Medical Officer
Chief Medical Officer
60.88K
--
Mr. Arthur S. Kirsch
Mr. Arthur S. Kirsch
Independent Director
Independent Director
45.71K
+28.00%
Dr. Howard Berman, Ph.D.
Dr. Howard Berman, Ph.D.
Independent Director
Independent Director
--
--
Dr. Janet Hammond, M.D., Ph.D.
Dr. Janet Hammond, M.D., Ph.D.
Chief Development Officer
Chief Development Officer
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Ms. Andrea J. Corcoran, J.D.
Ms. Andrea J. Corcoran, J.D.
Chief Financial Officer, Executive Vice President, Legal, and Secretary
Chief Financial Officer, Executive Vice President, Legal, and Secretary
717.31K
+1.18%
Dr. Jean-Pierre Sommadossi, Ph.D.
Dr. Jean-Pierre Sommadossi, Ph.D.
Chairman of the Board, President, Chief Executive Officer, Founder
Chairman of the Board, President, Chief Executive Officer, Founder
300.94K
--
Mr. John Vavricka
Mr. John Vavricka
Chief Commercial Officer
Chief Commercial Officer
134.59K
--
Mr. Bruno Lucidi
Mr. Bruno Lucidi
Independent Director
Independent Director
112.75K
+35.60%
Dr. Bruce Polsky, M.D.
Dr. Bruce Polsky, M.D.
Independent Director
Independent Director
95.21K
+45.12%
Dr. Polly A. Murphy, DVM, Ph.D.
Dr. Polly A. Murphy, DVM, Ph.D.
Independent Director
Independent Director
86.05K
+52.44%
收入明細
FY2022
FY2021
FY2020
暫無數據
地區USD
名稱
營收
佔比
United States
0.00
0.00%
業務
地區
暫無數據
股東統計
更新時間: 8月16日 週六
更新時間: 8月16日 週六
持股股東
股東類型
持股股東
持股股東
佔比
BML Capital Management LLC
9.59%
BlackRock Institutional Trust Company, N.A.
8.04%
JPM Partner LLC
7.39%
Fidelity Management & Research Company LLC
7.21%
Tang Capital Management, LLC
6.16%
其他
61.61%
持股股東
持股股東
佔比
BML Capital Management LLC
9.59%
BlackRock Institutional Trust Company, N.A.
8.04%
JPM Partner LLC
7.39%
Fidelity Management & Research Company LLC
7.21%
Tang Capital Management, LLC
6.16%
其他
61.61%
股東類型
持股股東
佔比
Investment Advisor
41.88%
Investment Advisor/Hedge Fund
13.57%
Hedge Fund
10.58%
Corporation
7.39%
Individual Investor
5.32%
Family Office
4.26%
Research Firm
1.09%
Pension Fund
0.35%
Bank and Trust
0.17%
其他
15.39%
機構持股
更新時間: 10月1日 週三
更新時間: 10月1日 週三
報告期間
機構數
持股數
持股佔比
持股變動
2025Q3
237
53.79M
67.78%
-6.81M
2025Q2
265
64.93M
76.05%
-9.01M
2025Q1
301
65.12M
76.13%
-9.02M
2024Q4
315
66.52M
78.76%
-10.39M
2024Q3
317
68.18M
80.76%
-8.54M
2024Q2
318
67.11M
79.66%
-7.40M
2024Q1
325
64.40M
76.50%
-9.70M
2023Q4
340
64.58M
77.29%
-9.97M
2023Q3
373
64.87M
77.77%
-27.38M
2023Q2
383
65.08M
78.05%
-32.20M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
BML Capital Management LLC
7.61M
9.59%
--
--
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
6.38M
8.04%
-272.13K
-4.09%
Jun 30, 2025
JPM Partner LLC
5.87M
7.39%
--
--
Apr 22, 2025
Fidelity Management & Research Company LLC
5.72M
7.21%
-298.26K
-4.96%
Jun 30, 2025
Tang Capital Management, LLC
4.89M
6.16%
+89.20K
+1.86%
Jun 30, 2025
The Vanguard Group, Inc.
4.89M
6.16%
+159.52K
+3.37%
Jun 30, 2025
Radoff Family Foundation
3.38M
4.26%
+275.00K
+8.86%
Apr 16, 2025
Bain Capital Life Sciences Investors, LLC
2.49M
3.13%
--
--
Jun 30, 2025
Geode Capital Management, L.L.C.
1.93M
2.43%
-51.76K
-2.62%
Jun 30, 2025
State Street Investment Management (US)
1.78M
2.24%
+5.71K
+0.32%
Jun 30, 2025
查看更多
持股ETF
更新時間: 11月6日 週四
更新時間: 11月6日 週四
機構名稱
佔比
ALPS Medical Breakthroughs ETF
0.13%
iShares Micro-Cap ETF
0.04%
Invesco Nasdaq Biotechnology ETF
0.03%
ProShares Ultra Nasdaq Biotechnology
0.02%
iShares Russell 2000 Value ETF
0.02%
Avantis US Small Cap Equity ETF
0.02%
iShares Biotechnology ETF
0.02%
Schwab U.S. Small-Cap ETF
0.01%
Global X Russell 2000 ETF
0.01%
ProShares Hedge Replication ETF
0.01%
查看更多
ALPS Medical Breakthroughs ETF
佔比0.13%
iShares Micro-Cap ETF
佔比0.04%
Invesco Nasdaq Biotechnology ETF
佔比0.03%
ProShares Ultra Nasdaq Biotechnology
佔比0.02%
iShares Russell 2000 Value ETF
佔比0.02%
Avantis US Small Cap Equity ETF
佔比0.02%
iShares Biotechnology ETF
佔比0.02%
Schwab U.S. Small-Cap ETF
佔比0.01%
Global X Russell 2000 ETF
佔比0.01%
ProShares Hedge Replication ETF
佔比0.01%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
